At Shift Bioscience, Daniel is making drugs for safer cellular rejuvenation in humans through the application of machine-learning 'driver' clocks to cellular reprogramming. Daniel is also a founding fellow of the OnDeck Longevity Biotech fellowship, a continuous community for people to come together to build, join, or invest in revolutionary longevity biotechnology startups.

Dr. Gordan Lauc is the Professor of Biochemistry and Molecular Biology at the University of Zagreb, Director of the National Centre of Scientific Excellence in Personalised Healthcare, honorary professor at the University of Edinburgh and the Kings College London, and member of the Johns Hopkins Society of Scholars. In 2017 he initiated the launch of the Human Glycome project and is one of its two co-directors.

Sebastian A. Brunemeier is a biotech founder and VC investor. He is CEO and Co-Founder of ImmuneAGE Pharma, a stealth-mode company developing small molecules for immune rejuvenation. Previously, he was Co-Founder and Chief Investment Officer at Cambrian Biopharma and a Principal at Apollo Health Ventures, the first and largest aging-focused venture capital fund in the world.

Long-time advocate for rejuvenation biotechnology and director of the aging research website Fight Aging. Reason is also the founder of Repair Biotechnologies,  a new venture that will focus on the development of gene therapies relevant to human rejuvenation.

Irina Conboy is Professor of Bioengineering, UC Berkeley, QB3(UCB/UCSF/UCSC) core faculty member and Core Member of UCB/UCSF Graduate Program. A key direction of her laboratory is to understand age-imposed and pathological changes in circulatory milieu and their impact on signaling pathways that regulate tissue maintenance and repair.